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Summary
Background.— The CONNECT study compared clinician adherence to guideline-recommendedsyndrome; secondary prevention therapies prescribed at discharge for patients hospitalized for acute coro-
Adherence;
Coronary angioplasty;
Clinical practice
guidelines;
Revascularization
nary syndrome (ACS) in those managed initially with percutaneous coronary intervention (PCI;
revascularized) and those who did not undergo revascularization.
Methods.— Patients aged greater than or equal to 18 years, hospitalized for a documented ST-
segment elevation or non-ST-segment elevation ACS, were enrolled consecutively over 1 month
at 238 sites in France.
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Results.— Compared with revascularized patients (n = 870), non-revascularized patients
(n = 706) were signiﬁcantly older, and a greater proportion were women, had high-blood pres-
sure, type-2 diabetes or a history of atherothrombotic or cardiac disease, but a smaller
proportion had a history of coronary angioplasty. On discharge, non-revascularized patients
were prescribed beta-blockers, aspirin, statins, angiotensin-converting enzyme inhibitors or
adenosine diphosphate receptor antagonists less frequently than revascularized patients. An
adherence score greater than or equal to 80% (at least four of the ﬁve recommended agents
prescribed at discharge) was found in 96.7% of revascularized patients and 74.4% of non-
revascularized patients (P < 0.001).
Conclusions.— Despite a similar or even higher level of cardiovascular risk, non-revascularized
ACS patients were prescribed guideline-recommended secondary prevention therapy less fre-
quently than revascularized patients.
© 2010 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Syndromes coronaires
aigus ;
Angioplastie
coronaire ;
Revascularisation
Résumé
Objectifs.— L’étude CONNECT a comparé la prise en charge thérapeutique, à la sortie de
l’hôpital au décours d’un syndrome coronaire aigu (SCA), des patients ayant bénéﬁcié d’une
revascularisation coronaire percutanée par rapport aux patients non revascularisés, au moyen
d’un score d’adhésion aux recommandations européennes.
Méthodes.— Les patients âgés d’au moins 18 ans, et présentant un SCA avec ou sans sus-
décalage du segment ST, ont été inclus, de fac¸on consécutive, sur une période d’un mois par
238 centres investigateurs franc¸ais.
Résultats.— Comparés aux patients revascularisés (n = 870), les patients non revascularisés
étaient signiﬁcativement plus âgés, plus fréquemment des femmes, et présentaient plus
souvent des antécédents d’hypertension artérielle, de diabète de type 2, d’insufﬁsance
cardiaque, d’insufﬁsance rénale, avec une moindre fréquence d’antécédents d’angioplastie
coronaire. À la sortie de l’hôpital, les patients non revascularisés bénéﬁciaient moins sou-
vent d’un traitement par bêtabloquants, aspirine, statines, inhibiteurs de l’enzyme de
conversion (IEC), antagonistes des récepteurs à l’ADP par rapport aux patients revas-
cularisés. Un score d’adhésion aux traitements BASIC supérieur ou égal à 80 % (au
moins quatre traitements recommandés présents sur l’ordonnance de sortie) était observé
chez 96,7 % de patients revascularisés et chez 70,4 % de patients non revascularisés
(p < 0,001).
Conclusion.— Alors même que leur niveau de risque était au moins équivalent sinon supérieur,
les patients présentant un SCA et non revascularisés recevaient moins souvent à la sortie de
ents
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oronary disease remains the principal cause of death in
he Western world, with acute coronary syndrome (ACS)
ontributing greatly to cardiovascular morbidity and mortal-
ty. The constant advances in the treatments available have
ade effective therapeutic management of ACS extremely
omplex [1]. Recently, international clinical practice guide-
ines were published to deﬁne the optimum therapeutic
trategies for the management of ACS by cardiologists [2—6].
t is important for these guidelines to be implemented
y cardiologists when treating patients with ACS because
dherence to guidelines is associated with a better patient
rognosis, not only in the acute phase of the syndrome but
lso in the long-term for secondary prevention [7—10].
The intervention-based strategy plays a major role in
he management of acute-phase patients because of the
ardiovascular beneﬁts demonstrated in numerous ran-
omized trials [11]. International guidelines, European
s well as North American, therefore advocate early
t
p
p
ivalidés par rapport aux patients revascularisés.
s droits réservés.
oronary angiography in anticipation of revascularization
3—6]. In France, this approach is facilitated by the often
asy and rapid access to a department of interventional
ardiology.
Several recent studies have found that the inter-
entional management of patients hospitalized for ACS
ould appear to be followed by better secondary preven-
ion management than that of non-revascularized patients
9,12,13]. We designed and conducted the CONNECT study
‘‘observational study of the adherence to international
uidelines in the management of acute coronary syn-
rome patients both during hospitalization and at discharge,
n revascularized as compared with non-revascularized
atients’’) to determine whether the same differences in
atient management exist in hospitals in France, both for
econdary prevention and during the acute phase, and
he possible reasons for less than optimal management of
atients who do not receive revascularization. The ultimate
urpose of examining current management of ACS in France
s to stimulate efforts to improve patient care.
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Methods
The CONNECT study is a prospective, cross-sectional, obser-
vational, multicentre survey conducted in metropolitan
France.
Hospital-based cardiologists in public or private cardi-
ology units treating patients with acute-phase ACS were
invited to participate in the survey. Patient management was
entirely at the discretion of the treating physicians. Patient
informed consent was not required. The study protocol was
reviewed by the National Council of the Order of Physicians
and was performed in accordance with French regulatory
requirements, the Declaration of Helsinki and the principles
of Good Epidemiologic Practice.
Patients
Male and female patients aged greater than or equal to
18 years who were hospitalized for ST-segment elevation
ACS (Q-wave myocardial infarction [MI], STEMI) or non-
ST-segment elevation ACS (non-Q-wave MI [non-ST-segment
elevation myocardial infarction, NSTEMI]) and unstable
angina, and who had not undergone coronary artery bypass
graft (CABG) surgery for the present episode and who were
not currently participating in a therapeutic trial of a medic-
inal product were enrolled in the study at the time of their
discharge from hospital. Participating physicians recruited
the ﬁrst four consecutive patients who met the selection
and revascularization criteria and the ﬁrst four consecu-
tive patients who met selection and non-revascularization
criteria over the period of 1 month at each study cen-
ter. Study investigators used the standard revascularization
and non-revascularization criteria of their cardiology unit.
Revascularization was by percutaneous coronary interven-
tion (PCI), which was deﬁned as coronary angioplasty with
or without stenting. Patients in either group could receive
ﬁbrinolytic treatment; non-revascularized patients were not
excluded if they received pharmacological reperfusion ther-
apy with ﬁbrinolytics.
Data collection
Physicians completed a standardized case report form
to collect information on patient clinical characteristics,
cardiovascular risk factors, medical history, clinical exam-
ination, laboratory test results, details of the intervention-
based strategy, the treatments prescribed during the acute
phase (hospitalization), treatments and reasons for non-
prescription at discharge (for treatments for secondary
prevention). Reasons were selected from the following list:
absence of indication; contraindication; replaced by another
therapeutic class; poor tolerability; deemed to have an inad-
equate beneﬁt-to-risk ratio; refused by patient; and other.
Study endpoints
The main objective was to compare the therapeutic man-
agement at discharge of patients who had presented
with ACS who underwent revascularization with those who
received conservative treatment without revascularization,
both overall and according to the type of ACS (with or with-
out ST-segment elevation) by comparing the proportion of
c
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atients with a ‘good’ adherence score. Adherence scores
ere calculated by assigning one point for prescription
f any of each of the following treatments as recom-
ended for secondary prevention in the European Society
f Cardiology guidelines on the management of ST-segment
levation myocardial infarction (STEMI) and non-ST-segment
levation ACS (NSTE ACS): beta-blockers, aspirin, 3-hydroxy-
-methylglutaryl-coenzyme A reductase inhibitors (statins),
nd angiotensin-converting enzyme (ACE) inhibitors or
denosine diphosphate (ADP) receptor antagonists [14,15].
ne point was assigned when a treatment was not prescribed
ecause of the presence of a contraindication to that treat-
ent because this was considered to be adherence, and thus
educing bias in the interpretation of guideline adherence.
he score for each patient was expressed as a percentage
f the maximum possible score (ﬁve points). Good adher-
nce was deﬁned as an adherence score of greater than
r equal to 80% (at least four of the ﬁve recommended
reatments).
The secondary objectives included the following: a
omparison between revascularized and non-revascularized
atients (and according to the type of ACS) for clinician
dherence to recommendations for patient management at
ischarge and patient management in the acute phase; an
nalysis of the predictors of clinician non-adherence; and
n analysis of the reasons for lack of prescription of sec-
ndary prevention therapies on discharge. An exploratory
nalysis comparing the risk of death and ischaemic events
n the NSTE ACS group (using the thrombolysis in myocardial
nfarction [TIMI] risk score [16]) between revascularized and
on-revascularized patients was also conducted.
tatistical methods
ata from all patients enrolled in the study (the study pop-
lation) were analyzed descriptively as follows: the sample
ize, mean and standard deviation± SD, median and range
rom ﬁrst to third quartile were calculated for continuous
ariables, and the number and percentage in relation to the
otal number of patients was calculated for qualitative vari-
bles. Patients in the non-revascularized group who had a
ormal coronary angiography result were excluded from the
tatistical analysis in order to avoid bias in interpretation of
dherence to secondary prevention treatment.
The search for predictors of non-adherence was carried
ut using a multivariable logistic regression analysis incor-
orating variables such as characteristics of the evaluable
atients. The statistical analyses were carried out using SAS
oftware V8 (SAS Institute Inc, Cary, NC).
esults
total of 1735 patients were recruited at 238 sites between
eptember 2006 and June 2007, of whom 23 did not meet
election criteria. Thus, 1712 patients were included in
he study population, of whom 870 patients were revas-
ularized and 842 were not revascularized. In the latter
roup, 60% had a diagnostic coronary angiography of whom
ost had coronary lesions, but 136 had a normal result and
ere excluded from the evaluable patient population. Thus
esults are reported for 1576 patients.
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atients
atient demographic and clinical characteristics are pre-
ented in Tables 1 and 2. The mean age was 67.5± 14.7
ears and there was a predominance of men (69.8% of
atients). The proportion of overweight (body mass index
BMI]≥ 25 kg/m2 but < 30 kg/m2) or obese (BMI≥ 30 kg/m2)
atients was 43.3% and 18.6%, respectively. A family history
f early onset coronary disease, smoking, dyslipidaemia,
ypertension or diabetes mellitus was observed frequently
n this cohort (20.9—59.2%). Of the 1576 patients, 553 had
T
T
N
c
Table 1 Demographic and clinical characteristics of enrolled
Revascularized patients N
Sex, n (%) (n = 870) (
Male 652 (74.9) 4
Female 218 (25.1) 2
Age (years) (n = 870) (
Mean± SD 63.0± 13.9 7
Median (rangeb) 63.0 (52.0—75.0) 7
Age in years, n (%) (n = 870) (
< 50 161 (18.5) 4
50—59 215 (24.7) 8
60—69 167 (19.2) 1
70—79 210 (24.1) 1
80—89 113 (13.0) 2
≥ 90 4 (0.5) 4
BMI (kg/m2) (n = 837) (
Mean± SD 26.8± 4.2 2
Median (rangeb) 26.4 (24.1—29.1) 2
BMI class in kg/m2, n (%) (n = 837) (
< 25 299 (35.7) 2
25—30 373 (44.6) 2
≥ 30 165 (19.7) 1
Smoking, n (%) (n = 866) (
Non-smoker 301 (34.8) 3
Stopped > 1 year previously 248 (28.6) 2
Stopped between 1 month
and 1 year prior
32 (3.7) 2
Current smoker 285 (32.9) 1
Dyslipidaemia, n (%) (n = 868) (
Yes 5
Hypertension, n (%) (n = 870) (
Yes 467 (53.7) 4
Type 1 or 2 diabetes mellitus,
n (%)
(n = 870) (
Yes 200 (23.0) 2
Family history of early onsetc
coronary disease, n (%)
(n = 868) (
Yes 210 (24.2) 1
BMI = body mass index; SD = standard deviation.
a All group comparisons were conducted using a Chi-square test with t
b Ranges are quoted for ﬁrst to third quartiles.
c Deﬁned as before age 55 years in men and 65 years in women.P. Sabouret et al.
-wave MI (35.1%) and 1023 had NSTE ACS (64.9%). Of the
atter, 528 had non-Q-wave MI and 495 had unstable angina.
The non-revascularized patients were signiﬁcantly older
P < 0.001), had a greater proportion of women (P < 0.001),
nd more often had a history of hypertension (P < 0.001),
iabetes mellitus (P = 0.003) or heart failure (P < 0.001) com-
ared with revascularized patients (Tables 1 and 2; see
ables for other signiﬁcant between-group differences).
he risk of death and ischaemic events in patients with
STE ACS was higher in non-revascularized than revas-
ularized patients (Table 3). A TIMI score greater than
patients.
on-revascularized patients Total Pa
n = 706) (n = 1576) < 0.001
48 (63.5) 1100 (69.8)
58 (36.5) 548 (30.2)
n = 706) (n = 1576) < 0.001
3.0± 13.7 67.5± 14.7
6.5 (64.0—84.0) 70.0 (56.0—80.0)
n = 706) (n = 1576) < 0.001
8 (6.8) 209 (13.3)
6 (12.2) 301 (19.1)
03 (14.6) 270 (17.1)
90 (26.9) 400 (25.4)
37 (33.6) 350 (22.2)
2 (5.9) 46 (2.9)
n = 675) (n = 1512) 0.002
6.2± 4.6 26.5± 4.4
5.8 (23.1—28.6) 26.1 (23.7—28.9)
n = 675) (n = 1512) 0.084
78 (41.2) 577 (38.2)
81 (41.6) 654 (43.3)
16 (17.2) 281 (18.6)
n = 699) (n = 1565) < 0.001
42 (48.9) 643 (41.1)
19 (31.3) 467 (29.8)
1 (3.0) 53 (3.4)
17 (16.8) 402 (25.7)
n = 703) (n = 1571) 0.123
09 (58.6) 385 (54.8)
n = 705) (n = 1575) < 0.001
66 (66.1) 933 (59.2)
n = 705) (n = 1575) 0.003
09 (29.6) 409 (26.0)
n = 702) (n = 1570)
18 (16.8) 328 (20.9) < 0.001
he exception of BMI and age, where a Wilcoxon test was used.
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Table 2 Cardiovascular history and characteristics of the current episode of acute coronary syndrome of enrolled
patients.
Revascularized patients
(n = 870)
Non-revascularized patients
(n = 706)
Total
(n = 1576)
Pa
History of
NSTE ACSb 291 (33.4) 317 (44.9) 608 (38.6) < 0.001
Q-wave MI 238 (27.4) 190 (26.9) 428 (27.2) 0.84
Coronary angioplasty 301 (34.6) 115 (16.3) 416 (26.4) < 0.001
Aortocoronary bypass 21 (2.4) 67 (9.5) 88 (5.6) < 0.001
Known coronary
stenosis≥ 50%
131 (15.1) 171 (24.2) 302 (19.2) < 0.001
Stable angina 72 (8.3) 128 (18.1) 200 (12.7) < 0.001
Heart failure 56 (6.4) 153 (21.7) 209 (13.3) < 0.001
Ischaemic CVA 26 (3.0) 56 (7.9) 82 (5.2) < 0.001
PAD of the lower limbs 54 (6.2) 89 (12.6) 143 (9.1) < 0.001
Current episode
≥ 2 episodes of angina in the
24 h preceding
hospitalization
316 (36.3) 227 (32.2) 543 (34.5) 0.083
Q-wave MI 363 (41.7) 190 (26.9) 553 (35.1) < 0.001
Non Q-wave MI 259 (29.8) 269 (38.1) 528 (33.5)
Unstable angina 248 (28.5) 247(35.0) 495 (31.4)
Data are reported as number of patients (%). CVA = cerebrovascular accident; MI =myocardial infarction; NSTE ACS = non-ST-segment
elevation acute coronary syndrome; PAD =peripheral arterial disease.
a Group comparisons were conducted using the Chi-square test.
b Deﬁned as unstable angina or non-Q wave MI.
Table 3 Thrombolysis in myocardial infarction (TIMI) risk score in evaluable patients with non-ST-segment elevation
acute coronary syndrome.
Revascularized patients
(n = 554)
Non-revascularized patients
(n = 526)
Total
(n = 1080)
n 550 516 1066
Data missing 4 10 14
Low risk (< 4) 370 (67.3) 291 (56.4) 661 (62.0)
High risk (≥ 4) 180 (32.7) 225 (43.6) 405 (38.0)
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oData are reported as number of patients (%).
or equal to 4 was observed in a greater proportion of
non-revascularized patients (43.6% vs. 32.7%; statistical
between-group comparison not conducted). In addition,
systemic atherothrombotic disease with symptomatic pol-
yarterial lesions, which was deﬁned as patients with a
cerebrovascular accident and/or peripheral arterial disease
of the lower limbs, was observed more commonly in the
non-revascularized group (both P < 0.001 vs. revascularized
group) (Table 2).
Secondary prevention guideline adherenceThe proportion of patients in the evaluable patient popu-
lation with a ‘good’ adherence score (≥ 80%) at discharge
was 96.7% in the revascularized group and 74.4% in the non-
revascularized group (P < 0.001), with a greater probability
of adherence in the revascularized than non-revascularized
l
(
t
proup (odds ratio [OR]: 10.0; 95% conﬁdence intervals
CI]: 6.7—15.0). Of the patients with STEMI, the propor-
ion with a good adherence score was even higher than
n the overall group, both in revascularized (99.1%) and
on-revascularized (76.1%) patients and between-group dif-
erences were signiﬁcant (P < 0.001). Conversely, of the
atients without ST-segment elevation, this proportion was
maller than in the overall group, and was 95.3% in the revas-
ularized group versus 73.8% in the non-revascularized group
P < 0.001). Additionally, prescription at discharge of dual-
ntiplatelet therapy of aspirin plus ADP receptor antagonists
ccurred more commonly in the patients who were revascu-
arized compared with those who were not revascularized
98.5% vs. 56.9%; P < 0.001).
When analyzed by adherence score (secondary objec-
ive), there were more non-revascularized patients with
oor adherence than revascularized patients in the study
442
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Figure 1. Comparison of the guideline-adherence scores at
discharge for secondary prevention in revascularized and non-
revascularized patients with acute coronary syndromes.
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Figure 2. Comparison of the proportion of revascularized and
non-revascularized patients admitted for acute coronary syndrome
for whom guideline-recommended secondary prevention treat-
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[19]), US [20] and multinational (GRACE [9]) registry studiesent was not prescribed at discharge. ACE = angiotensin-converting
nzyme; ADP = adenosine diphosphate. *P < 0.01 vs. revascularized
roup.
opulation (Fig. 1). In fact, non-revascularized patients
eceived aspirin, beta-blockers, statins, ACE inhibitors or
DP receptor antagonists signiﬁcantly (P < 0.01) less often
han revascularized patients (Fig. 2; data are shown as
bsence of prescription in the study population).
easons for non-prescription of secondary
revention treatment in non-revascularized
atients
he most common reasons for lack of prescription of beta-
lockers in non-revascularized patients were the presence
f contraindications and substitution with another class of
reatment (50.0% and 15.4%, respectively). The proportion
f patients not prescribed an ACE inhibitor because of sub-
titution with another class of treatment was 24.5% in the
on-revascularized group, and because of an absence of
ndication was 19.0% in the non-revascularized group and
t
m
w
AP. Sabouret et al.
1.0% in the revascularized group. In both groups, con-
raindication to ACE inhibitor treatment was rarely given
s a reason for non-prescription. ADP receptor antago-
ists were not prescribed in non-revascularized patients
ecause of an absence of indication (32.3% of cases of
on-prescription) and a poor beneﬁt-to-risk ratio (25.7%
f cases), whereas, the presence of a contraindication
ccounted for only 15.7% of cases of non-prescription in
his group. This latter reason was, however, the most
ommonly cited reason for non-prescription of aspirin in
on-revascularized patients (35.1% of cases). The beneﬁt-
o-risk ratio of statin treatment was considered insufﬁcient
n just over one-third of cases of non-prescription of this
lass of treatment in the non-revascularized group (32.3%),
ollowed by absence of indication (21.5%).
redictors of secondary prevention guideline
on-adherence
actors predictive of guideline non-adherence at discharge
deﬁned as adherence score of < 80%) in the evaluable
atient population were unstable angina or NSTEMI, atrial
brillation, age greater than 80 years, the presence of
ife-threatening comorbidities, and a normal troponin level
Table 4). Conversely, previous revascularization, the pres-
nce of dyslipidaemia and more than two episodes of angina
n the 24 hours preceding hospitalization were predictive of
ood adherence.
cute-phase guideline adherence
he same trends in guideline adherence were observed in
cute-phase management, with non-revascularized patients
eceiving recommended treatments less often than revascu-
arized patients. Fewer patients in the non-revascularized
roup had a ‘good’ adherence score (≥ 80%) for acute-phase
reatment compared with the revascularized group (72.6%
s. 92.0% of patients). Notably, ADP receptor antagonists
ere prescribed less frequently at admission for patients
ho did not undergo revascularization than in those who
ere revascularized (51.0% vs. 72.4% of patients; P < 0.001).
iscussion
he CONNECT study has demonstrated the inadequacy of the
herapeutic management of non-revascularized patients,
egardless of the type of ACS that prompted their initial
ospitalization. This happens despite the fact that non-
evascularized patients presented more frequently than
evascularized patients with a history of cardiovascular
isease and comorbidities. Our analysis showed that beta-
lockers, ADP receptor antagonists and ACE inhibitors,
n particular, were under-prescribed at discharge in non-
evascularized patients (by 18—43%; see Fig. 2).
Our ﬁndings support those of previous French (OPERA
17]), European regional (Euro Heart [18], EUROASPIRE IIhat have highlighted the under-use of recommended phar-
acological secondary prevention treatments in patients
ith atherothrombotic or coronary heart disease [19,21] or
CS [9,17,18,20]. This under-use is particularly notable for
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Table 4 Multivariable analysis of factors predictive of clinician non-adherence to European clinical practice guidelines
on the management of patients with acute coronary syndromes at discharge after hospital admission for an acute episode.
Data are presented for 1576 patients (data missing for 167 patients).
Patients (%) Odds ratio (95% CI) P
Non-adherencea
(n = 176)
Good adherenceb
(n = 1233)
Previous revascularization
Noc 153 (14.8) 881 (85.2) 1.00
Yes 23 (6.1) 352 (93.9) 0.36 (0.22—0.59) < 0.001
Unstable angina or non-Q wave
MI
Noc 88 (10.2) 777 (89.8) 1.00
Yes 88 (16.2) 456 (83.8) 1.89 (1.32—2.70) < 0.001
Atrial ﬁbrillation
Noc 147 (11.2) 1167 (88.8) 1.00
Yes 29 (30.5) 66 (69.5) 2.45 (1.46—4.10) < 0.001
Age in years
< 50c 14 (7.3) 177 (92.7) 1.00 0.001
50—59 17 (6.2) 257 (93.8) 0.73 (0.35—1.54)
60—69 16 (6.9) 217 (93.1) 0.75 (0.35—1.60)
70—79 46 (12.6) 320 (87.4) 1.34 (0.70—2.56)
80—89 70 (22.7) 238 (77.3) 1.95 (1.01—3.74)
≥ 90 13 (35.1) 24 (64.9) 3.41 (1.34—8.68)
Life-threatening comorbidities
Noc 128 (10.5) 1089 (89.5) 1.00 0.001
Yes 48 (25.0) 144 (75.0) 1.95 (1.29—2.94)
Dyslipidaemia
Noc 99 (16.5) 501 (83.5) 1.00
Yes 77 (9.5) 732 (90.5) 0.61 (0.43—0.86) 0.005
Troponin concentration
Elevatedc 136 (11.9) 1009 (88.1) 1.00
Not elevated 40 (15.2) 224 (84.8) 1.76 (1.15—2.68) 0.009
≥ 2 episodes of angina in 24 h
preceding hospitalization
Noc 127 (13.8) 791 (86.2) 1.00
Yes 49 (10.0) 442 (90.0) 0.63 (0.43—0.92) 0.016
Sex
Malec 106 (10.8) 878 (89.2) 1.00
Female 70 (16.5) 355 (83.5) 1.16 (0.81—1.67) 0.42
CI = conﬁdence interval; MI =myocardial infarction.
a Deﬁned as an adherence score < 80%.
b
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bDeﬁned as an adherence score≥ 80%.
c Reference.
antiplatelet agents [9]. Despite the fact that more recent
follow-up registry studies have reported better use of phar-
macological treatments in the management of ACS [22—24],
our results suggest that there is still room for improvement
in France.The under-use of beta-blockers in our study (i.e., lack
of prescription in 18% of cases) was due to the presence of
contraindications or a substitution with another treatment
class. Contraindication was also one of the main reasons
for lack of prescription of this class of drug in a recently
c
s
o
o
4ublished French survey on the use of evidence-based ther-
pies in patients with NSTE ACS [25]. Our results suggest
hat, in the absence of contraindications, prescription of
eta-blockers is good overall.
Most of our patients received antiplatelet therapy at dis-
harge with aspirin, supporting the ﬁndings of two French
tudies [17,25] and the GRACE registry (aspirin given in 87%
f patients [9]). Yet, the under-prescription at discharge
f antiplatelet therapy with ADP receptor antagonists (by
3%) in our non-revascularized patient population is a cause
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or concern. The Euro Heart II survey [23], REACH [21] and
RACE [9] studies also reported less than optimal prescrip-
ion of ADP receptor antagonists for secondary prevention.
or example, 71% did not receive an ADP receptor antago-
ist (thienopyridine) in the GRACE registry study [9], with
his ﬁgure as low as 24% in Europe and 39% in the US [9].
he physicians in our study cited absence of indication and
n inadequate beneﬁt-to-risk ratio as the principal reasons
or a lack of prescription of ADP receptor antagonists at dis-
harge in non-revascularized patients. Similarly, a lack of
ndication for treatment was the main reason given by physi-
ians participating in the Euro Heart II survey of patients
ith ACS for non-prescription of thienopyridines [23]. Yet,
he CURE (Clopidogrel in Unstable angina to prevent Recur-
ent Events) study showed clear improvement in prognosis in
atients receiving clopidogrel in addition to standard ther-
py (as discussed next) [26].
Indeed, dual-antiplatelet therapy was prescribed more
requently in revascularized patients in our study, and by
mplication, in patients who received a stent. In the GRACE
tudy, treatment with ADP receptor antagonists (usually in
ombination with aspirin) was signiﬁcantly more common
mongst revascularized patients [9], and a similar trend
as noted in a French survey [25]. This suggests clini-
ians have the perception that antiplatelet dual therapy
s appropriate only for revascularized patients, particu-
arly those receiving a stent. Whereas in the CURE study
26—28] (where 21% of patients were revascularized [27]),
eneﬁts of antiplatelet dual therapy were consistent across
ifferent patient subgroups, that is, regardless of whether
atients were revascularized or not [26], and by implica-
ion, whether they had received a stent or not. The problem
hen is clinician’s knowledge of clinical practice guidelines
nd the evidence from large clinical trials on which the
uideline recommendations are based, including the CURE
tudy. Antiplatelet dual therapy with aspirin plus clopidogrel
educed the risk of major cardiovascular events (compo-
ite endpoint of death from cardiovascular causes, non-fatal
I or stroke) over a mean follow-up of 1 year in patients
ith NSTE ACS [26]. Current guidelines therefore recom-
end long-term dual-antiplatelet therapy with aspirin and
lopidogrel (the latter for 12 months) as secondary preven-
ion treatment, provided neither agent is contraindicated,
n ACS patients [4,6].
Under-prescription of secondary prevention with an ACE
nhibitor in non-revascularized patients was not attributable
o the presence of contraindications (this was cited rarely
s a reason for lack of prescription), rather replacement
y another therapeutic class was the main reason, cited in
4.5% of cases of non-prescription in our study. It seems that
linicians in our study were not aware of the full poten-
ial use of ACE inhibitors as described in clinical practice
uidelines or that they are unconvinced of the beneﬁt in
igh-risk patients [4,6]. In the absence of contraindications,
he under-prescription of ACE inhibitors may place patients
ith coronary disease at greater risk of a cardiovascular
vent.Finally, guideline adherence for the prescription
f statins at discharge was relatively good in non-
evascularized and revascularized patients and was in
ine with that reported in other French studies [17,25].
tatins are considered standard in the secondary prevention
b
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rmamentarium, and are associated with a 21% reduction
n the incidence of major cardiovascular events when they
educe serum low-density lipoprotein levels by 1mM [29].
linicians have readily adopted guideline recommendations
o use statins, as described in the EUROASPIRE surveys
here there was a signiﬁcant (P < 0.0001) increase of 68%
n the use of statins between the ﬁrst and third surveys
spanning 12 years) [22].
In multivariable analyses, clinician adherence was pre-
icted by the previous coronary angioplasty event, the
resence of dyslipidaemia and two episodes or more of
ngina in the 24 hours preceding hospitalization. We hypoth-
size that these situations are where cardiologists are more
ikely to pay greater attention to patient management,
nd in the case of dyslipidaemia would be more likely to
rescribe statins. Our results are supported by the CRU-
ADE study, which showed that invasive management of
atients with NSTE ACS was associated with improved guide-
ine adherence both at discharge and in the acute phase
12]. Among the predictors of non-adherence, lack of use of
ppropriate therapies in the very elderly or those with life-
hreatening comorbidities may be attributable to a fear of
pplying guidelines to these high-risk patients.
Adherence to treatment guidelines for the acute phase
irrored that of the secondary prevention setting over-
ll, suggesting that if a treatment is not prescribed in the
cute phase, it is not prescribed at discharge either. In
articular, ADP receptor antagonists were under-utilized in
on-revascularized patients in this setting in our study, being
rescribed in only 51.0% of patients, which is a value broadly
imilar to that observed in other studies (52—58% of patients
n OPERA [17], CRUSADE [24] and GRACE [30]). Indeed, a
ecent analysis of CRUSADE data by Alexander et al. sup-
orts our conclusion that non-revascularized patients are
ndertreated; about 50% of patients with NSTE ACS who did
ot undergo PCI (within 24 hours) did not receive guideline-
ecommended therapy with clopidogrel [31]. As a result,
atient outcomes are adversely affected; clopidogrel given
n the acute phase (i.e., within 24 hours of hospitalization)
as associated with lower risk of in-hospital mortality than
on-use of clopidogrel (OR: 0.68; 95% CI: 0.61—0.77) [31].
All of the available data in the literature, including
egistry data, stress the need to optimize the prescrib-
ng of acute-phase and secondary prevention treatments
or ACS patients in order to improve concordance between
vidence-based medicine and current practice, and as a
esult, patient outcomes.
To reduce the potential for bias in our analysis
f secondary prevention management, we excluded 136
atients with a normal coronary angiography from the
on-revascularized group (16.1%). Moreover, the observed
nder-use of recommended pharmacological treatments in
he management of ACS in our study cannot be explained by
he presence of contraindications to treatment because the
dherence score was weighted to account for contraindica-
ions.
One can argue that in the group of patients with unsta-
le angina and no coronary angiography, the absence of
roof of coronary disease may explain the difference in
he non-adherence factors. An analysis was performed
omparing non-revascularized patients with an abnormal
oronary angiography versus those who did not undergo
f
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coronary angiography. Among the patients with no coro-
nary angiography in the non-revascularized group, 31.4% had
unstable angina, whereas 38.1% of patients with coronary
angiography had unstable angina. This difference was not
statistically signiﬁcant (P = 0.1). In the group with unsta-
ble angina and no coronary angiography, signiﬁcantly more
patients have a history of CABG, cardiac insufﬁciency and
comorbidities compared with patients in the group with
coronary angiography. Similar differences were observed
between both groups (with or without coronary angiogra-
phy for patients with Q-wave and non Q-wave MI [data not
shown]). These data are concordant with the major reasons
given for no coronary angiography, which were age, comor-
bidity and renal insufﬁciency. Therefore, the coronary status
by itself (no proof of coronary disease) does not explain the
differences in the non-adherence factors.
Any potential bias in the recruitment of cardiologists such
as can exist in this type of study, which is based on volun-
tary participation by doctors, was eliminated by comparing
the general characteristics of the investigating cardiologists
with those of a general population of French cardiologists,
for whom data was obtained from the DREES (French Direc-
torate for Research, Studies, Evaluation and Statistics) at
the time the study was set up. No physicians were excluded
from participating in this study on the basis of this analysis.
In addition, any potential bias in the selection of patients
was avoided by enrolling the ﬁrst four consecutive patients
who met the selection and revascularization criteria and the
ﬁrst four who met selection and non-revascularization cri-
teria. The conduct of the study might have led more to an
overestimation rather than underestimation of the level of
guideline adherence as compared with usual clinical prac-
tice.
Conclusion
Patients with ACS who do not undergo revascularization
by PCI during their initial hospitalization receive guideline-
recommended secondary prevention treatment at discharge
less often than revascularized patients, even though their
cardiovascular risk level is at least equivalent to or greater
than that of revascularized patients. Patient characteristics
such as age, the presence of comorbidities, atrial ﬁbrilla-
tion, history of unstable angina or NSTEMI are predictive of
clinician non-adherence to clinical guidelines as illustrated
by under-prescribing of recommended treatments, lead-
ing to a paradoxical under-treatment of high-risk patients.
Progress is therefore essential for the optimization of treat-
ment of non-revascularized ACS patients and thus to improve
their cardiovascular prognosis in the short andmedium term.
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